Pure Global AI
NCT06351761Not yet recruiting

WIBOFA - Validation of SCT02 With ECG-App for Detection of AF

Validation of Withings BeamO With Withings ECG-App for the Detection of Atrial Fibrillation
WithingsClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
Atrial Fibrillation
Drug/Device/Intervention
Investigational Device (Withings SCT02) 30 second Electrocardiogram recording
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Withings
Location
Boca Raton,Miami,Créteil, France,United States of America
Timeline & enrollment
Phase
N/A
Start date
May 01, 2024
End date
Mar 01, 2025
Enrollment
270 participants
Primary outcome

Co-primary outcome 1 - Sensitivity of Investigational Device,Co-primary outcome 2 - Specificity of Investigational Device

Summary

The aim of the study is to evaluate the performance of Withings SCT02 with embedded Withings
 ECG-app in the automatic detection of atrial fibrillation

ICD-10 classifications
Chronic atrial fibrillationPersistent atrial fibrillationParoxysmal atrial fibrillationAtrial fibrillation and flutterAtrial fibrillation and atrial flutter, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06351761
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06351761 through Pure Global AI's free database. This phase not specified trial is sponsored by Withings and is currently Not yet recruiting. The study focuses on Atrial Fibrillation. Target enrollment is 270 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.